• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Pulmonx Corporation

    5/7/25 11:47:10 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care
    Get the next $LUNG alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 4)


    Pulmonx Corp

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    745848101

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    745848101


    1Names of Reporting Persons

    Morgan Stanley
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,359,202.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,390,737.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,390,737.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.5 %
    12Type of Reporting Person (See Instructions)

    HC, CO


    SCHEDULE 13G

    CUSIP No.
    745848101


    1Names of Reporting Persons

    Morgan Stanley Capital Services LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,897,537.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,897,537.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,897,537.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.3 %
    12Type of Reporting Person (See Instructions)

    BD, CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Pulmonx Corp
    (b)Address of issuer's principal executive offices:

    700 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063
    Item 2. 
    (a)Name of person filing:

    1: Morgan Stanley 2: Morgan Stanley Capital Services LLC
    (b)Address or principal business office or, if none, residence:

    1: 1585 Broadway, New York, NY 10036 ;2: 1585 Broadway, New York, NY 10036
    (c)Citizenship:

    1: Delaware 2: Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    745848101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    8.5  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See Exhibit 99.2
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Morgan Stanley
     
    Signature:Chris O'Hara
    Name/Title:Authorized Signatory, Morgan Stanley
    Date:05/07/2025
     
    Morgan Stanley Capital Services LLC
     
    Signature:Chris O'Hara
    Name/Title:Authorized Signatory, Morgan Stanley Capital Services LLC
    Date:05/07/2025
    Exhibit Information

    EXHIBIT NO. EXHIBITS ------------------ ------------------------------------ 99.1 Joint Filing Agreement 99.2 Item 7 Information * Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).

    Get the next $LUNG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LUNG

    DatePrice TargetRatingAnalyst
    3/10/2025$17.00Buy
    D. Boral Capital
    12/11/2024$17.00 → $7.50Buy → Neutral
    Citigroup
    6/4/2024$12.00Buy
    Lake Street
    2/23/2024$16.00 → $14.00Overweight → Equal Weight
    Wells Fargo
    9/5/2023$18.00Buy
    Craig Hallum
    2/27/2023$10.00 → $15.00Equal Weight → Overweight
    Wells Fargo
    1/3/2023$8.00Neutral → Underperform
    BofA Securities
    12/12/2022$14.00 → $10.00Neutral → Buy
    Citigroup
    More analyst ratings

    $LUNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

      SC 13G/A - Pulmonx Corp (0001127537) (Subject)

      11/14/24 7:47:49 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

      SC 13G/A - Pulmonx Corp (0001127537) (Subject)

      11/12/24 10:34:16 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

      SC 13G/A - Pulmonx Corp (0001127537) (Subject)

      11/8/24 10:35:45 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pulmonx to Present at the Bank of America Securities 2025 Health Care Conference

      REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx") a global leader in minimally invasive treatments for severe lung disease, today announced the company will be presenting at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 9:35 AM PT / 12:35 PM ET. A live and archived webcast of the presentation will be available on "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx's Zephyr® Endobronchial Va

      5/1/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx Reports First Quarter 2025 Financial Results

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights Achieved worldwide revenue of $22.5 million in the first quarter of 2025, a 20% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $8.3 million in international revenue in the first quarter of 2025, representing 39% year-over-year growth and an increase of 43% on a constant currency basisDelivered $14.2 million in U.S. revenue in the first quarter of 20

      4/30/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025

      REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni

      4/16/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      8/22/24 6:41:17 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director French Glendon E. Iii sold $157,000 worth of shares (20,000 units at $7.85), decreasing direct ownership by 2% to 991,974 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      3/21/25 6:14:28 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer & PAO Joshi Mehul sold $102,414 worth of shares (14,384 units at $7.12) and was granted 108,000 shares, increasing direct ownership by 73% to 221,986 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      3/5/25 6:12:01 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • PRESIDENT AND CEO Williamson Steven S. sold $197,699 worth of shares (27,689 units at $7.14) and was granted 181,696 shares, increasing direct ownership by 69% to 376,038 units (SEC Form 4)

      4 - Pulmonx Corp (0001127537) (Issuer)

      3/5/25 6:09:24 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Leadership Updates

    Live Leadership Updates

    See more
    • Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

      REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

      4/2/24 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

      REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of

      2/21/24 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • The Honest Company Announces Appointment of Michael Barkley, Alissa Hsu Lynch, and Andrea Turner to the Board of Directors

      LOS ANGELES, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The Honest Company (NASDAQ:HNST), a digitally-native consumer products company dedicated to creating clean- and sustainably-designed products spanning baby care, beauty, personal care, wellness and household care, today announced that Michael Barkley, Former Chief Executive Officer of Kind LLC, Alissa Hsu Lynch, Former Global Head of MedTech Strategy and Solutions for Google Cloud, and Andrea Turner, Former Senior Vice President, Global Customer Service & Logistics at Mondelēz International, Inc., have been appointed to its Board of Directors effective December 8, 2023. "We are pleased to welcome Michael, Alissa and Andrea to our board of dir

      12/11/23 9:00:00 AM ET
      $HNST
      $LUNG
      Catalog/Specialty Distribution
      Consumer Discretionary
      Medical/Dental Instruments
      Health Care

    $LUNG
    Financials

    Live finance-specific insights

    See more
    • Pulmonx Reports First Quarter 2025 Financial Results

      REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights Achieved worldwide revenue of $22.5 million in the first quarter of 2025, a 20% increase over the same period last year and an increase of 21% on a constant currency basisDelivered $8.3 million in international revenue in the first quarter of 2025, representing 39% year-over-year growth and an increase of 43% on a constant currency basisDelivered $14.2 million in U.S. revenue in the first quarter of 20

      4/30/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx to Report First Quarter 2025 Financial Results on April 30, 2025

      REDWOOD CITY, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Wednesday, April 30, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni

      4/16/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results

      REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior yearAchieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase over the same period last year on an as reported and constant currency basisSet a record of $15.9 million and $56.5 million in U.S. revenue for the fourth quarter 2024 and the full year 20

      2/19/25 4:05:00 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Pulmonx Corporation

      SCHEDULE 13G/A - Pulmonx Corp (0001127537) (Subject)

      5/7/25 11:47:10 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Pulmonx Corporation

      10-Q - Pulmonx Corp (0001127537) (Filer)

      5/2/25 4:18:52 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Pulmonx Corp (0001127537) (Filer)

      4/30/25 4:10:52 PM ET
      $LUNG
      Medical/Dental Instruments
      Health Care

    $LUNG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • D. Boral Capital initiated coverage on Pulmonx with a new price target

      D. Boral Capital initiated coverage of Pulmonx with a rating of Buy and set a new price target of $17.00

      3/10/25 8:07:21 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Pulmonx downgraded by Citigroup with a new price target

      Citigroup downgraded Pulmonx from Buy to Neutral and set a new price target of $7.50 from $17.00 previously

      12/11/24 7:54:19 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Pulmonx with a new price target

      Lake Street initiated coverage of Pulmonx with a rating of Buy and set a new price target of $12.00

      6/4/24 8:21:23 AM ET
      $LUNG
      Medical/Dental Instruments
      Health Care